A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
about
Buprenorphine for the management of opioid withdrawalBuprenorphine for the management of opioid withdrawalThe Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the LiteratureUpdate on the clinical use of buprenorphine: in opioid-related disordersA randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification.Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatmentThe Place of Adoption in the NIDA Clinical Trials Network.Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.Client and counselor attitudes toward the use of medications for treatment of opioid dependence.Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceFrom research to the real world: buprenorphine in the decade of the Clinical Trials NetworkUnderstanding attitudes towards use of medication in substance abuse treatment: A multilevel approach.Partnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network.Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomesDirect care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefsOpioid dependence treatment: options in pharmacotherapy.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Study results from the Clinical Trials Network's first 10 years: where do they lead?Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?HIV/AIDS and drug use in China--interactions, impacts, and issues.Buprenorphine for opioid dependenceThe effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment.Buprenorphine: a (relatively) new treatment for opioid dependence.Predictors of dropout from inpatient opioid detoxification with buprenorphine: a chart reviewBuprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes.Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.Buprenorphine implant for opioid addictionGender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network.Retention of under-represented minorities in drug abuse treatment studiesOpioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based studyHIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study.Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network.Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network.Gender differences in the rates and correlates of HIV risk behaviors among drug abusers.Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network.Clinical correlates of health-related quality of life among opioid-dependent patients
P2860
Q24240149-93D76481-332A-455A-B3B8-E882B5E700ABQ24246088-E46FAA3F-3BA3-4D85-9844-16CE76D35571Q26741943-5E6A4509-D75B-46A9-A063-D6151F570A74Q26829140-A5431B4A-0358-4751-BFF4-80FAC2F5F7FCQ30578204-3D123567-106F-4438-812A-E43D4D6B49B8Q30938843-888D92D5-1D36-4090-A57C-A3BA21AE01D6Q33263687-70537735-5C04-4586-8FF6-0E2F74538218Q33622979-96D8AEF6-B6B4-4333-BC65-3F4A3A77B651Q33653252-A4E88E2F-BBB7-4624-AE2E-2F957F1E26A2Q33763021-F52AC8D3-42F9-42E1-975E-B6B5E6B1D554Q33783250-D2D96C2D-3695-4B14-B2BD-635525D014D4Q33783274-574A3E51-BBCC-4B24-ABEB-763734EE6A18Q33791771-1AB271B0-1FC4-4742-8C27-703E695D636AQ33793165-3B5DA578-28F4-49FD-A359-5863A18C3DF0Q33795318-878F26EA-2ED0-40BC-9295-3E725A4AB842Q33817446-087EBF1F-01D5-4DCC-BD02-E77C1F955F21Q33868638-2E9CA977-5B60-4C1C-86CB-547D9014852AQ33870389-AD1490C0-736A-41EA-B668-D48F968E5B8DQ34018862-FA51B56E-1E5A-401D-BF9C-CDD49BAA888EQ34018867-0DA1F87F-B8AF-4A02-AA54-40F6EC789BFBQ34119447-FE9CB9C1-27EC-4283-8C90-7249402450D9Q34119459-B66D29D9-AD7A-403B-86F2-EA848BCF9583Q34226309-3DB11A72-712A-4777-A8AC-8198A112DDAEQ34363688-F70215B0-0BAF-4F51-B396-86AF404BE959Q34365302-1C8090BA-4FFB-4E1B-9A8F-3CD2D6F58C91Q34501351-3C225BF4-1FF9-4DE4-BAD5-7DDDAD236AC7Q34517116-5B2372D7-05A6-41AD-BBF4-BB1647CEBADDQ34604313-91930063-51AF-4657-B7D9-7CF55CA96C65Q34615450-5FAE2731-2F3B-4652-84E9-4B025924E6E2Q34820000-EE0FADEC-A6BE-4FF9-A85E-1D66FF2488B3Q35065975-C485FE56-084D-42B9-B9E3-954693CFBA08Q35070260-9502356A-EE2D-49A5-AC0D-FAAAAE9BD8F0Q35090939-8D1BE4EA-3E10-4D6A-A729-ED2FED72F0C5Q35139642-83F2F1C8-73BA-4A10-B14D-5674609F0C3EQ35143605-AF411462-E6F7-4486-A92A-184208E1E827Q35148079-93C0ECDB-610E-494E-848F-2F52E3BCD623Q35185527-309E6D06-4352-4079-959B-AB67E6FB9D6DQ35203629-FDAE8C0F-7215-48F1-A7CE-5D79AFF6EAADQ35206845-B89B1C11-82B8-445B-A241-29C8CA37421BQ35226390-849C95F9-7037-4126-81E1-4DEC0729F4C3
P2860
A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A multi-center randomized tria ...... Abuse Clinical Trials Network
@ast
A multi-center randomized tria ...... Abuse Clinical Trials Network
@en
A multi-center randomized tria ...... Abuse Clinical Trials Network
@nl
type
label
A multi-center randomized tria ...... Abuse Clinical Trials Network
@ast
A multi-center randomized tria ...... Abuse Clinical Trials Network
@en
A multi-center randomized tria ...... Abuse Clinical Trials Network
@nl
prefLabel
A multi-center randomized tria ...... Abuse Clinical Trials Network
@ast
A multi-center randomized tria ...... Abuse Clinical Trials Network
@en
A multi-center randomized tria ...... Abuse Clinical Trials Network
@nl
P2093
P2860
P3181
P1433
P1476
A multi-center randomized tria ...... Abuse Clinical Trials Network
@en
P2093
Betty Buchan
Dean Babcock
Debbie Orr
Douglas Ziedonis
George Woody
Jeffrey J Annon
Jonathan Krejci
Judy Harrer
Leslie Amass
P2860
P304
P3181
P356
10.1111/J.1360-0443.2005.01154.X
P407
P577
2005-08-01T00:00:00Z